Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 8/20 | 0.41 |
| ▸ | JAK3 | P52333 | 7/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20849664 | 1.00 | DPP4 (0.42) | DPP4DPP7TEAD1JAK3DPP8 | |
| SCHEMBL20399740 | 1.00 | DPP4 (0.42) | DPP4DPP7TEAD1JAK3DPP8 | |
| SCHEMBL22296413 | 0.90 | JAK3 (0.41) | DPP4DPP7JAK3 | |
| SCHEMBL17179524 | 0.90 | JAK3 (0.41) | DPP4DPP7JAK3 | |
| SCHEMBL17179528 | 0.90 | JAK3 (0.41) | DPP4DPP7JAK3 | |
| SCHEMBL29728768 | 0.87 | TEAD1 (0.43) | TEAD1JAK3TEAD3 | |
| SCHEMBL17833394 | 0.82 | JAK3 (0.40) | TEAD1JAK3 | |
| SCHEMBL17833391 | 0.82 | JAK3 (0.40) | TEAD1JAK3 | |
| SCHEMBL17833396 | 0.82 | JAK3 (0.40) | TEAD1JAK3 | |
| SCHEMBL20161816 | 0.81 | CYP1A2 (0.36) | TEAD1JAK3TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022235864-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | DPP4 2096/4885DPP7 1776/4885TEAD1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.